CAR-T cell therapy targeting the B lymphocyte surface antigen CD19 is most effective for relapsed and refractory lymphomas (5–8), and several CAR-T products are currently approved as second-line therapeutic regimens for relapsed and refractory large B cell lymphomas, including DLBCL (9–12). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.